Repros Therapeutics Inc. (NASDAQ:RPRX) shares shot up 3.9% during trading on Thursday . The stock traded as high as $2.15 and last traded at $2.12, with a volume of 87,080 shares traded. The stock had previously closed at $2.04.

Separately, Zacks Investment Research downgraded shares of Repros Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $2.00.

The company’s market cap is $51.55 million. The stock has a 50 day moving average of $1.81 and a 200-day moving average of $1.58.

Repros Therapeutics (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. Equities research analysts predict that Repros Therapeutics Inc. will post ($0.69) earnings per share for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.